EBS

$8.08

Post-MarketAs of Mar 17, 8:00 PM UTC

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$8.08
Potential Upside
131.3%
Whystock Fair Value$18.69
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commerc...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$424.36M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
8.69
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.44
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
10.46%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.19

Recent News

Barrons.com
Mar 17, 2026

Mpox Is on the Rise in the U.S. 3 Vaccine Stocks Worth a Second Look.

New York City officials have confirmed the first case of a more severe strain case of mpox. Mpox, formerly known as monkeypox, is a viral infection characterized by a flu-like fever and rash that can last weeks. It’s caused by a virus in the same family as smallpox, though it’s less contagious and less dangerous.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 10, 2026

How The Investment Narrative For Emergent BioSolutions (EBS) Is Shifting After The $12 Target Reset

Emergent BioSolutions is back in focus after analysts cut their price target from $15 to $12, prompting a fresh look at what is and is not working in the story. Bulls view the new $12 mark as a reset of expectations rather than a rejection of the longer term case, while bears see it as recognition that earlier optimism on earnings was too generous. As you read on, you will see how these competing views shape the evolving narrative and what to watch next in the numbers and commentary. Stay...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 28, 2026

Emergent Biosolutions Q4 Earnings Call Highlights

Emergent Biosolutions (NYSE:EBS) reported fourth-quarter and full-year 2025 results on a Feb. 26, 2026 earnings call, with management highlighting progress on its multi-year transformation plan, improved profitability and cash generation, and a 2026 outlook that reflects the absence of a major one-t

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 27, 2026

Emergent BioSolutions Inc (EBS) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue ...

Emergent BioSolutions Inc (EBS) reports strong EBITDA growth and operational efficiency despite revenue declines and market uncertainties.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Feb 26, 2026

Emergent Biosolutions: Q4 Earnings Snapshot

GAITHERSBURG, Md. AP) — Emergent Biosolutions Inc. EBS) on Thursday reported a loss of $54.6 million in its fourth quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.